...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Archives of dermatological research. >Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma.
【24h】

Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma.

机译：血管紧张素转化酶基因插入/缺失多态性与基底细胞癌的风险降低的关系。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The incidence of basal cell carcinoma (BCC) is significantly reduced in individuals treated with inhibitors of angiotensin I-converting enzyme (ACE) that produces angiotensin II. The objective of this study was to investigate the possible association of a functional polymorphism in the ACE gene, which affects its transcription, with risk for BCC. In DNA samples of 92 patients with BCC and 103 healthy controls of Greek origin and comparable age and gender, we studied the ACE gene insertion/deletion (I/D) polymorphism. Fisher's exact test was used for comparison of allele and genotype frequencies between the control and patients' groups. The detected low expression I allele frequency in the group of BCC patients was significantly decreased compared to controls (15.8 vs. 31.1 %, respectively; P = 0.001). ID heterozygotes exhibited 3.06 times lower BCC risk, compared with DD homozygotes (P = 0.001; OR = 0.327, 95 % CI = 0.174-0.615). The protective role of I allele was particularly prominent in women (P = 0.007, OR = 0.299, 95 % CI = 0.125-0.716), while for men it exhibited a marginal level (P = 0.041). These findings indicate that the low expression ACE I allele carriers have a decreased risk for BCC. The protective effect of the ID genotype against BCC may be explained by a possible underlying mechanism involving the effect of produced angiotensin II levels on its receptors due to putatively different binding affinity.
机译：在产生血管紧张素II的血管紧张素I-转换酶（ACE）的抑制剂治疗的个体中，基础细胞癌（BCC）的发生率显着降低。本研究的目的是探讨函数多态性在ACE基因中的可能关联，影响其转录，具有BCC的风险。在92例BCC患者的DNA样本和103名希腊源性和性别的健康控制患者中，我们研究了ACE基因插入/缺失（I / D）多态性。 Fisher的确切试验用于对照和患者群体之间的等位基因和基因型频率进行比较。与对照组相比，该组BCC患者的检测到的低表达I等位基因频率显着降低（分别为31.1％; P = 0.001）。与DD纯合子相比，ID杂合子表现出较低的BCC风险较低的3.06倍（P = 0.001;或= 0.327,95％CI = 0.174-0.615）。 I等位基因的保护作用在女性中尤其突出（P = 0.007，或= 0.299,95％CI = 0.125-0.716），而对于男性，它表现出边际水平（P = 0.041）。这些发现表明，低表达ACE I等位基因载体对BCC的风险降低。 ID基因型对BCC的保护作用可以通过涉及产生的血管紧张素II水平对其受体产生的影响的可能潜在的机制来解释，由于令人牢的结合亲和力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号